PD 1323012
Latest Information Update: 30 Mar 1995
Price :
$50 *
At a glance
- Originator Pfizer
- Class Antihyperlipidaemics
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia